North America Acinetobacter Pneumonia Therapeutics Market Size & Outlook
North America acinetobacter pneumonia therapeutics market, 2018-2030 (US$M)
Related Markets
North America acinetobacter pneumonia therapeutics market highlights
- The North America acinetobacter pneumonia therapeutics market generated a revenue of USD 112.2 million in 2023.
- The market is expected to grow at a CAGR of 6.5% from 2024 to 2030.
- In terms of segment, cephalosporins was the largest revenue generating drug class in 2023.
- Sulbactam is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 112.2 million |
| Market revenue in 2030 | USD 174.3 million |
| Growth rate | 6.5% (CAGR from 2023 to 2030) |
| Largest segment | Cephalosporins |
| Fastest growing segment | Sulbactam |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cephalosporins , Fluoroquinolone , Glycylcycline , Carbapenem , β-Lactam antibiotics, Sulbactam, Aminoglycoside , Polymyxins, Tetracycline, Sulfonamide, Other Drug Classes |
| Key market players worldwide | Pfizer Inc, Merck & Co Inc, GlaxoSmithKline, AstraZeneca PLC, Novartis AG ADR, Johnson & Johnson, Sanofi SA, Bayer AG, Basilea Pharmaceutica Ltd |
Other key industry trends
- In terms of revenue, North America region accounted for 37.3% of the global acinetobacter pneumonia therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 133.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Acinetobacter Pneumonia Therapeutics Market Scope
Acinetobacter Pneumonia Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America acinetobacter pneumonia therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to acinetobacter pneumonia therapeutics market will help companies and investors design strategic landscapes.
Cephalosporins was the largest segment with a revenue share of 14.62% in 2023. Horizon Databook has segmented the North America acinetobacter pneumonia therapeutics market based on cephalosporins , fluoroquinolone , glycylcycline , carbapenem , β-lactam antibiotics, sulbactam, aminoglycoside , polymyxins, tetracycline, sulfonamide, other drug classes covering the revenue growth of each sub-segment from 2018 to 2030.
- North America Acinetobacter Pneumonia Therapeutics Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Cephalosporins
- Fluoroquinolone
- Glycylcycline
- Carbapenem
- β-Lactam antibiotics
- Sulbactam
- Aminoglycoside
- Polymyxins
- Tetracycline
- Sulfonamide
- Other Drug Classes
- North America Acinetobacter Pneumonia Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Parenteral
- Oral
- Other Route of Administrations
Reasons to subscribe to North America acinetobacter pneumonia therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America acinetobacter pneumonia therapeutics market databook
-
Our clientele includes a mix of acinetobacter pneumonia therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America acinetobacter pneumonia therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into North America acinetobacter pneumonia therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America acinetobacter pneumonia therapeutics market report size, by country, 2018-2030 (US$M)
North America Acinetobacter Pneumonia Therapeutics Market Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
